PMID- 37806666
OWN - NLM
STAT- MEDLINE
DCOM- 20231101
LR  - 20231101
IS  - 1464-5157 (Electronic)
IS  - 0265-6736 (Linking)
VI  - 40
IP  - 1
DP  - 2023
TI  - The use of histotripsy as intratumoral immunotherapy beyond tissue ablation-the 
      rationale for exploring the immune effects of histotripsy.
PG  - 2263672
LID - 10.1080/02656736.2023.2263672 [doi]
AB  - Mechanical high-intensity focused ultrasound (M-HIFU), which includes 
      histotripsy, is a non-ionizing, non-thermal ablation technology that can be 
      delivered by noninvasive methods. Because acoustic cavitation is the primary 
      mechanism of tissue disruption, histotripsy is distinct from the conventional 
      HIFU techniques resulting in hyperthermia and thermal injury. Phase I human 
      trials have shown the initial safety and efficacy of histotripsy in treating 
      patients with malignant liver tumors. In addition to tissue ablation, a promising 
      benefit of M-HIFU has been stimulating a local and systemic antitumor immune 
      response in preclinical models and potentially in the Phase I trial. Preclinical 
      studies combining systemic immune therapies appear promising, but clinical 
      studies of combinations have been complicated by systemic toxicities. 
      Consequently, combining M-HIFU with systemic immunotherapy has been demonstrated 
      in preclinical models and may be testing in future clinical studies. An 
      additional alternative is to combine intratumoral M-HIFU and immunotherapy using 
      microcatheter-placed devices to deliver both M-HIFU and immunotherapy 
      intratumorally. The promise of M-HIFU as a component of anti-cancer therapy is 
      promising, but as forms of HIFU are tested in preclinical and clinical studies, 
      investigators should report not only the parameters of the energy delivered but 
      also details of the preclinical models to enable analysis of the immune 
      responses. Ultimately, as clinical trials continue, clinical responses and immune 
      analysis of patients undergoing M-HIFU including forms of histotripsy will 
      provide opportunities to optimize clinical responses and to optimize application 
      and scheduling of M-HIFU in the context of the multi-modality care of the cancer 
      patient.
FAU - Osada, Takuya
AU  - Osada T
AD  - Department of Surgery, Duke University School of Medicine, Duke University, 
      Durham, NC, USA.
FAU - Jiang, Xiaoning
AU  - Jiang X
AD  - Department of Mechanical and Aerospace Engineering, College of Engineering, NC 
      State University, Raleigh, NC, USA.
FAU - Zhao, Yuhang
AU  - Zhao Y
AD  - Sonokine Bioscience, Chapel Hill, NC, USA.
FAU - Chen, Mengyue
AU  - Chen M
AD  - Department of Mechanical and Aerospace Engineering, College of Engineering, NC 
      State University, Raleigh, NC, USA.
FAU - Kreager, Benjamin C
AU  - Kreager BC
AD  - Department of Mechanical and Aerospace Engineering, College of Engineering, NC 
      State University, Raleigh, NC, USA.
FAU - Wu, Huaiyu
AU  - Wu H
AD  - Department of Mechanical and Aerospace Engineering, College of Engineering, NC 
      State University, Raleigh, NC, USA.
FAU - Kim, Howuk
AU  - Kim H
AD  - Department of Mechanical Engineering, School of Engineering, Inha University, 
      Incheon, Republic of South Korea.
FAU - Ren, Jun
AU  - Ren J
AD  - Department of Surgery, Duke University School of Medicine, Duke University, 
      Durham, NC, USA.
FAU - Snyder, Joshua
AU  - Snyder J
AD  - Department of Surgery and Cell Biology, Duke University School of Medicine, Duke 
      University, Durham, NC, USA.
FAU - Zhong, Pei
AU  - Zhong P
AD  - Thomas Lord Department of Mechanical Engineering and Material Science, Pratt 
      School of Engineering, Duke University, Durham, NC, USA.
FAU - Morse, Michael A
AU  - Morse MA
AD  - Department of Medicine, Duke University School of Medicine, Duke University, 
      Durham, NC, USA.
FAU - Lyerly, H Kim
AU  - Lyerly HK
AD  - Department of Surgery, Pathology, and Integrative Immunobiology, Duke University 
      School of Medicine, Duke University, Durham, NC, USA.
LA  - eng
PT  - Journal Article
DEP - 20231008
PL  - England
TA  - Int J Hyperthermia
JT  - International journal of hyperthermia : the official journal of European Society 
      for Hyperthermic Oncology, North American Hyperthermia Group
JID - 8508395
SB  - IM
MH  - Humans
MH  - *High-Intensity Focused Ultrasound Ablation/methods
MH  - *Carcinoma, Hepatocellular
MH  - *Liver Neoplasms
MH  - Immunotherapy
OTO - NOTNLM
OT  - Mechanical high-intensity focused ultrasound (M-HIFU)
OT  - histotripsy
OT  - immunotherapy
EDAT- 2023/10/09 00:41
MHDA- 2023/11/01 12:44
CRDT- 2023/10/08 20:12
PHST- 2023/11/01 12:44 [medline]
PHST- 2023/10/09 00:41 [pubmed]
PHST- 2023/10/08 20:12 [entrez]
AID - 10.1080/02656736.2023.2263672 [doi]
PST - ppublish
SO  - Int J Hyperthermia. 2023;40(1):2263672. doi: 10.1080/02656736.2023.2263672. Epub 
      2023 Oct 8.